Michael Barbella, Managing Editor08.05.22
GreenBone Ortho SpA has found a local distribution partner for its bone scaffold.
The company recently signed an agreement with Abiogen Pharma SpA for the distribution of b.Bone, its patented 3D bone regenerative scaffold derived from biomorphic transformation of Rattan wood. Abiogen will market and distribute b.Bone 3D bone substitute across Italy.
"We are very excited about this agreement with Abiogen," declared Diogo C. Moreira-Rato, non-executive GreenBone board member and former Johnson & Johnson senior executive. "We are confident this agreement will lead not only to successful commercial results for b.Bone in the Italian market but will also be a driving force for the development of other European markets where GreenBone is focusing its efforts.”
Millions of people have bone repair surgery to treat bone loss resulting from trauma, cancer or bone degenerative conditions. It normally requires multiple surgery with significant risks for patients and very high social and healthcare costs. Bone replacement options are: bone transplant (currently the best option) or bone grafts (ceramic, polymer and metal alloys), but medical professionals are grappling with the limitations of existing solutions.
GreenBone's b.Bone is a nature-inspired solution designed to meet the highest standards in tissue engineered performance. b.Bone 3D scaffold is a Rattan wood-derived highly porous biomimetic material. It mimics natural bone chemistry, morphology and 3D architecture. CE-mark has been granted in 2019 for a portfolio of solutions to serve various orthopedic surgical needs with indication of use in orthopedic and trauma surgery, including large bone defects. More than 60 patients have been treated as of April 2022. New indications of use are under development including spine surgery.
The technology was conceived at the Institute of Science and Technology for Ceramics (ISTEC), part of the Italian National Research Council (CNR).
"The agreement with Abiogen represents the successful completion of GreenBone efforts from lab to market, transforming innovative research into a commercially valuable product,” said Lorenzo Pradella, co-founder of GreenBone Ortho SpA.
Founded in 2014, GreenBone Ortho SpA has recently established a second facility located in Roncadelle (Brescia), Italy, to develop bigger production capacity to serve international markets. b.Bone proprietary 3D scaffold is biomimetic biomaterial from Rattan wood-derived materials; this new generation highly porous graft mimics natural bone chemistry, morphology and 3D architecture. The company received CE Mark approval in December 2019 for various orthopedic surgical solutions and has raised €22 million in equity investments. Last year, GreenBone received a €2.5 million grant from the EIC Accelerator program to develop a new indication for spine fusion surgery.
The history of Abiogen Pharma dates back to 1917, the year of the foundation of the Galenic Institute, then the Gentili Institute, by Commendatore Alfredo Gentili. In 1997, the family business was sold to Merck Sharp & Dhome. With the aim of keeping alive 100 years of entrepreneurial commitment by the family, Abiogen Pharma maintains a part of the drug list, the staff, the structures, the Research Center and development projects.
The company recently signed an agreement with Abiogen Pharma SpA for the distribution of b.Bone, its patented 3D bone regenerative scaffold derived from biomorphic transformation of Rattan wood. Abiogen will market and distribute b.Bone 3D bone substitute across Italy.
"We are very excited about this agreement with Abiogen," declared Diogo C. Moreira-Rato, non-executive GreenBone board member and former Johnson & Johnson senior executive. "We are confident this agreement will lead not only to successful commercial results for b.Bone in the Italian market but will also be a driving force for the development of other European markets where GreenBone is focusing its efforts.”
Millions of people have bone repair surgery to treat bone loss resulting from trauma, cancer or bone degenerative conditions. It normally requires multiple surgery with significant risks for patients and very high social and healthcare costs. Bone replacement options are: bone transplant (currently the best option) or bone grafts (ceramic, polymer and metal alloys), but medical professionals are grappling with the limitations of existing solutions.
GreenBone's b.Bone is a nature-inspired solution designed to meet the highest standards in tissue engineered performance. b.Bone 3D scaffold is a Rattan wood-derived highly porous biomimetic material. It mimics natural bone chemistry, morphology and 3D architecture. CE-mark has been granted in 2019 for a portfolio of solutions to serve various orthopedic surgical needs with indication of use in orthopedic and trauma surgery, including large bone defects. More than 60 patients have been treated as of April 2022. New indications of use are under development including spine surgery.
The technology was conceived at the Institute of Science and Technology for Ceramics (ISTEC), part of the Italian National Research Council (CNR).
"The agreement with Abiogen represents the successful completion of GreenBone efforts from lab to market, transforming innovative research into a commercially valuable product,” said Lorenzo Pradella, co-founder of GreenBone Ortho SpA.
Founded in 2014, GreenBone Ortho SpA has recently established a second facility located in Roncadelle (Brescia), Italy, to develop bigger production capacity to serve international markets. b.Bone proprietary 3D scaffold is biomimetic biomaterial from Rattan wood-derived materials; this new generation highly porous graft mimics natural bone chemistry, morphology and 3D architecture. The company received CE Mark approval in December 2019 for various orthopedic surgical solutions and has raised €22 million in equity investments. Last year, GreenBone received a €2.5 million grant from the EIC Accelerator program to develop a new indication for spine fusion surgery.
The history of Abiogen Pharma dates back to 1917, the year of the foundation of the Galenic Institute, then the Gentili Institute, by Commendatore Alfredo Gentili. In 1997, the family business was sold to Merck Sharp & Dhome. With the aim of keeping alive 100 years of entrepreneurial commitment by the family, Abiogen Pharma maintains a part of the drug list, the staff, the structures, the Research Center and development projects.
